Skip to main content

Table 5 Incidence of adverse events and short-term neonatal outcomes

From: Infant flow biphasic nasal continuous positive airway pressure (BP- NCPAP) vs. infant flow NCPAP for the facilitation of extubation in infants' ≤ 1,250 grams: a randomized controlled trial

Variable*

BP-NCPAP

(N = 67)

NCPAP

(N = 69)

P value

Adverse events

Nasal septum breakdown [N (%)]

6 (8.9%)

9 (13%)

0.59

Eyelid edema [N (%)]

3 (4.5%)

2 (2.8%)

0.68

Feeding intolerance [N (%)]

8 (11.9%)

17 (25%)

0.08

Abdominal distension [N (%)]

16 (23.8%)

8 (12%)

0.07

Pneumothorax [N (%)]

0

0

 

Short-term neonatal outcomes

Mortality [N (%)]

3 (4%)

5 (7%)

0.49

New-onset sepsis after extubation [N (%)]

8 (12%)

5 (7%)

0.35

Bronchopulmonary dysplasia (oxygen dependency at 36 weeks PMA) [N (%)]

21 (31.3%)

22 (31.8%)

1.0

Necrotising enterocolitis [N (%)]

7 (10.4%)

7 (10.1%)

0.95

Grade 3/4 IVH/PVL

1/62 (1.6%)

5/65(7.7%)

0.41

ROP > stage 2 [N (%)]

11 (17%)

3 (5%)

0.02

Patent ductus arteriosus [N (%)]

36 (53.7%)

35 (51%)

0.82

  1. *IVH = Intraventricular hemorrhage, N = Number, % = Percent, PVL = Periventricular leucomalacia, ROP = Retinopathy of prematurity